JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

Search

Quanterix Corp

Închisă

SectorSănătate

3.11 2.3

Rezumat

Modificarea prețului

24h

Curent

Minim

2.96

Maxim

3.19

Indicatori cheie

By Trading Economics

Venit

10M

-23M

Vânzări

3.7M

44M

Marjă de profit

-52.712

Angajați

450

EBITDA

15M

-17M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+80.33% upside

Dividende

By Dow Jones

Următoarele câștiguri

6 mai 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-145M

151M

Deschiderea anterioară

0.81

Închiderea anterioară

3.11

Sentimentul știrilor

By Acuity

15%

85%

29 / 347 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Neutral Evidence

Quanterix Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

30 apr. 2026, 23:08 UTC

Câștiguri

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 apr. 2026, 23:07 UTC

Câștiguri

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 apr. 2026, 22:20 UTC

Câștiguri

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

30 apr. 2026, 23:48 UTC

Market Talk

Nikkei May Rise After Gains on Wall Street -- Market Talk

30 apr. 2026, 23:47 UTC

Market Talk

Global Equities Roundup: Market Talk

30 apr. 2026, 23:47 UTC

Market Talk

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

30 apr. 2026, 23:27 UTC

Market Talk

Liontown Lithium Recovery Expected to Improve -- Market Talk

30 apr. 2026, 23:22 UTC

Câștiguri

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

30 apr. 2026, 23:20 UTC

Market Talk

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

30 apr. 2026, 22:52 UTC

Câștiguri

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 apr. 2026, 22:33 UTC

Câștiguri

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

30 apr. 2026, 22:32 UTC

Câștiguri

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

30 apr. 2026, 22:32 UTC

Câștiguri

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

30 apr. 2026, 22:24 UTC

Achiziții, Fuziuni, Preluări

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

30 apr. 2026, 22:23 UTC

Achiziții, Fuziuni, Preluări

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

30 apr. 2026, 22:23 UTC

Achiziții, Fuziuni, Preluări

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

30 apr. 2026, 22:23 UTC

Achiziții, Fuziuni, Preluări

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

30 apr. 2026, 22:11 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30 apr. 2026, 22:11 UTC

Market Talk

Global Equities Roundup: Market Talk

30 apr. 2026, 22:11 UTC

Market Talk

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

30 apr. 2026, 22:05 UTC

Câștiguri

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

30 apr. 2026, 21:57 UTC

Câștiguri

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

30 apr. 2026, 21:56 UTC

Câștiguri

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

30 apr. 2026, 21:56 UTC

Câștiguri

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

30 apr. 2026, 21:55 UTC

Câștiguri

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

30 apr. 2026, 21:54 UTC

Câștiguri

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

30 apr. 2026, 21:54 UTC

Câștiguri

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

30 apr. 2026, 21:53 UTC

Câștiguri

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

30 apr. 2026, 21:49 UTC

Câștiguri

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

30 apr. 2026, 21:49 UTC

Câștiguri

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Comparație

Modificare preț

Quanterix Corp Așteptări

Obiectiv de preț

By TipRanks

80.33% sus

Prognoză pe 12 luni

Medie 5.5 USD  80.33%

Maxim 7 USD

Minim 4 USD

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruQuanterix Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

2 ratings

0

Cumpărare

2

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

5.34 / 6.015Suport & Rezistență

Termen scurt

Neutral Evidence

Termen mediu

Bullish Evidence

Termen lung

No Evidence

Sentiment

By Acuity

29 / 347 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Quanterix Corp

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
help-icon Live chat